| Overview |
| bs-0732R-Cy5 |
| Cyclooxygenase 2 Polyclonal Antibody, Cy5 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Others |
| Dog, Cow, Sheep, Pig, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse Cyclooxygenase 2 |
| 501-604/604 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 19225 |
| Q05769 |
| Cytoplasm |
| COX2; Cox-2; PHS-2; Pghs2; TIS1; PGHS-2; Prostaglandin G/H synthase 2; Cyclooxygenase-2; Glucocorticoid-regulated inflammatory cyclooxygenase; Gripghs; Macrophage activation-associated marker protein P71/73; PES-2; PHS II; Prostaglandin H2 synthase 2; PGH synthase 2; Prostaglandin-endoperoxide synthase 2; TIS1 protein; Ptgs2; Pghs-b |
| Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz